158 related articles for article (PubMed ID: 34850863)
1. Atherosclerosis progression in antiphospholipid syndrome is comparable to diabetes mellitus: a 3 year prospective study.
Evangelatos G; Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2022 Aug; 61(8):3408-3413. PubMed ID: 34850863
[TBL] [Abstract][Full Text] [Related]
2. Carotid and femoral atherosclerosis in antiphospholipid syndrome: Equivalent risk with diabetes mellitus in a case-control study.
Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Tektonidou MG
Semin Arthritis Rheum; 2018 Jun; 47(6):883-889. PubMed ID: 29150207
[TBL] [Abstract][Full Text] [Related]
3. 7-year follow-up atherosclerotic plaque progression in patients with antiphospholipid syndrome versus diabetes mellitus and healthy controls.
Evangelatos G; Tentolouris N; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38321577
[TBL] [Abstract][Full Text] [Related]
4. Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: Association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques.
Bolla E; Tentolouris N; Sfikakis PP; Tektonidou MG
Front Immunol; 2022; 13():1077166. PubMed ID: 36700208
[TBL] [Abstract][Full Text] [Related]
5. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus.
Torricelli AK; Ugolini-Lopes MR; Bonfá E; Andrade D
Lupus; 2020 Mar; 29(3):256-262. PubMed ID: 31986962
[TBL] [Abstract][Full Text] [Related]
6. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response.
Conti F; Spinelli FR; Alessandri C; Pacelli M; Ceccarelli F; Marocchi E; Montali A; Capozzi A; Buttari B; Profumo E; Sorice M; Arca M; Valesini G; Riganò R
Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):661-8. PubMed ID: 24436371
[TBL] [Abstract][Full Text] [Related]
7. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study.
Vlachoyiannopoulos PG; Kanellopoulos PG; Ioannidis JP; Tektonidou MG; Mastorakou I; Moutsopoulos HM
Rheumatology (Oxford); 2003 May; 42(5):645-51. PubMed ID: 12709540
[TBL] [Abstract][Full Text] [Related]
8. Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE.
Panopoulos S; Drosos GC; Konstantonis G; Sfikakis PP; Tektonidou MG
Lupus Sci Med; 2023 Mar; 10(1):. PubMed ID: 36868585
[TBL] [Abstract][Full Text] [Related]
9. Atherosclerotic plaques occur in absence of intima-media thickening in both systemic sclerosis and systemic lupus erythematosus: a duplexsonography study of carotid and femoral arteries and follow-up for cardiovascular events.
Frerix M; Stegbauer J; Kreuter A; Weiner SM
Arthritis Res Ther; 2014 Feb; 16(1):R54. PubMed ID: 24548804
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus.
Bolla E; Tentolouris N; Sfikakis PP; Tektonidou MG
Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34921093
[TBL] [Abstract][Full Text] [Related]
11. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome.
Jiménez S; García-Criado MA; Tàssies D; Reverter JC; Cervera R; Gilabert MR; Zambón D; Ros E; Bru C; Font J
Rheumatology (Oxford); 2005 Jun; 44(6):756-61. PubMed ID: 15757967
[TBL] [Abstract][Full Text] [Related]
12. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.
McMahon M; Skaggs BJ; Grossman JM; Sahakian L; Fitzgerald J; Wong WK; Lourenco EV; Ragavendra N; Charles-Schoeman C; Gorn A; Karpouzas GA; Taylor MB; Watson KE; Weisman MH; Wallace DJ; Hahn BH
Arthritis Rheumatol; 2014 Jan; 66(1):130-9. PubMed ID: 24449580
[TBL] [Abstract][Full Text] [Related]
13. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus.
Papazoglou N; Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2024 Jan; 63(1):50-57. PubMed ID: 37086440
[TBL] [Abstract][Full Text] [Related]
14. Impact of Antiphospholipid Syndrome and/or Systemic Lupus Erythematosus on the Long-term Adverse Cardiovascular Outcomes in Patients After Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.
Bundhun PK; Boodhoo KD; Long MY; Chen MH
Medicine (Baltimore); 2016 Mar; 95(12):e3200. PubMed ID: 27015221
[TBL] [Abstract][Full Text] [Related]
15. Subclinical atherosclerosis in Systemic Lupus Erythematosus: Comparable risk with Diabetes Mellitus and Rheumatoid Arthritis.
Tektonidou MG; Kravvariti E; Konstantonis G; Tentolouris N; Sfikakis PP; Protogerou A
Autoimmun Rev; 2017 Mar; 16(3):308-312. PubMed ID: 28147263
[TBL] [Abstract][Full Text] [Related]
16. Progression of subclinical atherosclerosis in systemic lupus erythematosus versus rheumatoid arthritis: the impact of low disease activity.
Kravvariti E; Konstantonis G; Sfikakis PP; Tektonidou MG
Rheumatology (Oxford); 2018 Dec; 57(12):2158-2166. PubMed ID: 30102390
[TBL] [Abstract][Full Text] [Related]
17. Comparable or higher prevalence of comorbidities in antiphospholipid syndrome vs rheumatoid arthritis: a multicenter, case-control study.
Panopoulos S; Thomas K; Georgiopoulos G; Boumpas D; Katsiari C; Bertsias G; Drosos AA; Boki K; Dimitroulas T; Garyfallos A; Papagoras C; Katsimbri P; Tziortziotis A; Adamichou C; Kaltsonoudis E; Argyriou E; Vosvotekas G; Sfikakis PP; Vassilopoulos D; Tektonidou MG
Rheumatology (Oxford); 2021 Jan; 60(1):170-178. PubMed ID: 32596727
[TBL] [Abstract][Full Text] [Related]
18. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.
Perez-Sanchez C; Barbarroja N; Messineo S; Ruiz-Limon P; Rodriguez-Ariza A; Jimenez-Gomez Y; Khamashta MA; Collantes-Estevez E; Cuadrado MJ; Aguirre MA; Lopez-Pedrera C
Ann Rheum Dis; 2015 Jul; 74(7):1441-9. PubMed ID: 24618261
[TBL] [Abstract][Full Text] [Related]
19. [Cardiovascular risk factors in systemic lupus erythematosus and in antiphospholipid syndrome].
Sarzi-Puttini P; Atzeni F; Carrabba M
Minerva Med; 2003 Apr; 94(2):63-70. PubMed ID: 12858154
[TBL] [Abstract][Full Text] [Related]
20. [Traditional risk factors for cardiovascular disease in primary antiphospholipid syndrome (APS) when compared with secondary APS: a study with 96 patients].
Ribeiro AR; Carvalho JF
Acta Reumatol Port; 2010; 35(1):36-41. PubMed ID: 20505627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
